{"groups":[{"description":"Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/m² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/m² IV on Days 1, 2, 3 for 6 cycles.","id":"FG000","title":"Fludarabine+Cyclophosphamide (FC)"},{"description":"Rituximab and FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: rituximab 375 mg/m² IV on Day 1; fludarabine 25 mg/m² IV on Days 2, 3, 4; cyclophosphamide 250 mg/m² IV on Days 2, 3, 4. Cycles 2-6: rituximab 500 mg/m² IV on Day 1; fludarabine 25 mg/m² IV on Days 1, 2, 3; cyclophosphamide 250 mg/m² IV on Days 1, 2, 3.","id":"FG001","title":"Fludarabine+Cyclophosphamide+Rituximab (FCR)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"276"},{"groupId":"FG001","numSubjects":"276"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"272"},{"groupId":"FG001","numSubjects":"274"}],"type":"Safety Population; Received Study Drug"},{"achievements":[{"comment":"Completed 6 Cycles of Treatment","groupId":"FG000","numSubjects":"167"},{"comment":"Completed 6 Cycles of Treatment","groupId":"FG001","numSubjects":"181"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"109"},{"groupId":"FG001","numSubjects":"95"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}